Your browser doesn't support javascript.
loading
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Liu, Joyce F; Ray-Coquard, Isabelle; Selle, Frederic; Poveda, Andrés M; Cibula, David; Hirte, Hal; Hilpert, Felix; Raspagliesi, Francesco; Gladieff, Laurence; Harter, Philipp; Siena, Salvatore; Del Campo, Josep Maria; Tabah-Fisch, Isabelle; Pearlberg, Joseph; Moyo, Victor; Riahi, Kaveh; Nering, Rachel; Kubasek, William; Adiwijaya, Bambang; Czibere, Akos; Naumann, R Wendel; Coleman, Robert L; Vergote, Ignace; MacBeath, Gavin; Pujade-Lauraine, Eric.
Afiliação
  • Liu JF; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Ray-Coquard I; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Selle F; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Poveda AM; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Cibula D; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Hirte H; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Hilpert F; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Raspagliesi F; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Gladieff L; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Harter P; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Siena S; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Del Campo JM; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Tabah-Fisch I; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Pearlberg J; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Moyo V; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Riahi K; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Nering R; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Kubasek W; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Adiwijaya B; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Czibere A; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Naumann RW; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Coleman RL; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Vergote I; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • MacBeath G; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
  • Pujade-Lauraine E; Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer In
J Clin Oncol ; 34(36): 4345-4353, 2016 12 20.
Article em En | MEDLINE | ID: mdl-27998236
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Paclitaxel / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Paclitaxel / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article